Explore Lifecore Biomedical's Fair Values from the Community and select yours

Lifecore Biomedical (NASDAQ:LFCR) Full Year 2025 Results

Key Financial Results

• Revenue: US$128.9m (flat on FY 2024).
• Net loss: US$44.4m (down from US$9.33m profit in FY 2024).
• US$1.27 loss per share (down from US$0.31 profit in FY 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Lifecore Biomedical EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.5%.

In the last 12 months, the only revenue segment was Lifecore contributing US$128.9m. Notably, cost of sales worth US$88.6m amounted to 69% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to US$44.0m (52% of total expenses). Explore how LFCR's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US.

Performance of the American Life Sciences industry.

The company's shares are down 2.3% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 3 warning signs for Lifecore Biomedical that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.